About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Schizophrenia Clinical Trials | 4,235 Studies Recruiting

Clinical TrialsSchizophrenia

Schizophrenia Clinical Trials

Browse 4,235 clinical trials for schizophrenia. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 2581-2600 of 4,235 trials

CompletedPrevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional AntipsychoticsThis pilot study hypothesizes that diagnosed and undiagnosed prevalence of diabetes mellitus may differ across antipsychotioc medications in a community mental health center.NCT00224276 CompletedNicotine Replacement Therapy for Smoking Cessation in SchizophreniaThis proposal seeks to evaluate a pilot smoking cessation treatment program that will combine nicotine replacement therapy with or without bupropion sustained-release (SR) with…NCT00320723·Boston, Massachusetts Not yet recruitingHD-tDCS for HallucinationsOne in three patients with schizophrenia experiences hallucinations that are refractory to conventional pharmacotherapy.NCT06208176·Bron

Related Searches

Data from ClinicalTrials.govTerms

CompletedSmoking Relapse Prevention in SchizophreniaThis study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.NCT00320697·Boston, Massachusetts

RecruitingRandomized Withdrawal Study in Patients With SchizophreniaThe purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in…NCT06961968·Rogers, Arkansas and 21 others

CompletedRisperidone LA Heathcare Resource StudyThe primary objective of this pilot study is to evaluate the impact of switching 30 subjects from an existing antipsychotic to risperidone long acting on healthcare resource…NCT00272597·Coquitlam, British Columbia

UnknownEarly Diagnosis of Intracranial Infection After CraniotomyIntracranial infection are serious complications postoperatively in neurosurgical patients.NCT04215094·Guangzhou, Guangdong

UnknownShiatsu Adjuvant Therapy And Placebo For SchizophreniaIn the current study we will study the effect of adding acupressure (shiatsu) to conventional therapy in treating individuals with schizophrenia.NCT00788970·Jerusalem

TerminatedBilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations ResultsThe primary purpose of this study was to conduct fMRI neuroimaging studies prior to and subsequent to the rTMS intervention.NCT04548622·New Haven, Connecticut

UnknownKetogenic Diet for Psychotic DisordersDisturbances in glucose metabolism and glutamate neurotransmission feature in the pathophysiology of psychotic disorders.NCT03873922·Kuopio

RecruitingEffectiveness of Trauma Therapy Using Prolonged Exposure for Patients With PTSD and a Comorbid Psychotic DisorderPsychosis patients with comorbid PTSD will be treated with trauma therapy.NCT06048172·Hamburg

Active not recruitingCannabidiol for Treatment of Non-affective Psychosis and Cannabis UseThis trial examines the efficacy of cannabidiol (CBD) versus risperidone for treatment of psychosis in patients with non affective-psychosis and lifetime use of cannabis.NCT04105231·Glostrup Municipality

TerminatedThe Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) GenotypeThis study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia.NCT00548327·Bethesda, Maryland

CompletedDAAOI-2 add-on Treatment for Treatment-resistant SchizophreniaPharmacotherapy for schizophrenia has limitations such as residual positive and negative symptoms, cognitive deficits and intolerable side effects.NCT02532686·Taichung

Not yet recruitingValue of Voxel-Based Morphometry in SchizophreniaThis cross-sectional observational study investigates structural brain abnormalities in schizophrenia and nicotine use disorder (NUD), with a focus on understanding how these…NCT07108673

CompletedCognitive Behavioral Therapy Added to Risperidone for SchizophreniaThis study evaluated whether cognitive behavioral therapy (CBT), when added to risperidone treatment, improves cognitive function and serum brain-derived neurotrophic factor…NCT07609953·Makassar, South Sulawesi

CompletedThe Effects AZD8529 on Cognition and Negative Symptoms in SchizophrenicsThe purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with…NCT00986531·Philadelphia, Pennsylvania

CompletedComparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute SchizophreniaThe purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophreniaNCT00712686

RecruitingImmune Mechanisms of Antipsychotic Treatment ResponseThe aim of this study is to investigate the role of the immune system in psychotic symptoms and their response to treatment.NCT06687694·London, United Kingdom

CompletedRP5063 in Subjects With Schizophrenia or Schizoaffective DisorderThe objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.NCT01490086·Philadelphia, Pennsylvania and 14 others

PreviousPage 130 of 212Next